Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Refractory Grade 3a Follicular Lymphoma: early-phase trial registry

1 of 1 indexed Refractory Grade 3a Follicular Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Refractory Grade 3a Follicular Lymphoma: 1 US clinical trial tracked, 1 recruiting.

Refractory Grade 3a Follicular Lymphoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 1 of these trials.

Enrollment posture brief

Registry condition refractory-grade-3a-follicular-lymphoma

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Refractory Grade 3a Foll (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Refractory Grade 3a Follicular Lymphoma

Refractory Grade 3a Follicular Lymphoma lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Refractory Grade 3a Follicular Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Refractory Grade 3a Follicular Lymphoma is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Refractory Grade 3a Follicular Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Polatuzumab Vedotin Drug
1 trials
Mosunetuzumab Biological
1 trials
Magnetic Resonance Imaging Procedure
1 trials
Computed Tomography Procedure
1 trials
Biospecimen Collection Procedure
1 trials

US sites by state

Facility locations filed on Refractory Grade 3a Follicular Lymphoma trials. A trial with sites in several states counts in each.

California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Refractory Grade 3a Follicular Lymphoma page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Refractory Grade 3a Follicular Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • City of Hope Medical Center sponsors the most Refractory Grade 3a Follicular Lymphoma trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Grade 3a Follicular Lymphoma condition card totals 1 registered trials; most-linked intervention Polatuzumab Vedotin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.